
Phasing is the first AI-agentic clinical research company that revolutionizes drug discovery and clinical trials by integrating a specialized AI workforce with human experts. Their innovative model eliminates traditional billable hours, instead charging fixed prices tied to milestones, thus aligning incentives for shared success. Phasing's proprietary technology creates a unified AI-native platform that connects all aspects of clinical trials, enhancing efficiency and reducing delays. By leveraging AI at its core, they provide comprehensive end-to-end trials and targeted services, ensuring faster execution and higher data quality compared to traditional CROs.

Phasing is the first AI-agentic clinical research company that revolutionizes drug discovery and clinical trials by integrating a specialized AI workforce with human experts. Their innovative model eliminates traditional billable hours, instead charging fixed prices tied to milestones, thus aligning incentives for shared success. Phasing's proprietary technology creates a unified AI-native platform that connects all aspects of clinical trials, enhancing efficiency and reducing delays. By leveraging AI at its core, they provide comprehensive end-to-end trials and targeted services, ensuring faster execution and higher data quality compared to traditional CROs.